ProEncia Biotechnology Closes Pre-Seed Funding to Advance Next-Gen, Patent-Pending Periodontal Disease Treatment
Twin Cities-based ProEncia Biotechnology, a biopharma startup, today announced the company has closed significant pre-seed funding to advance its next-generation periodontal disease treatment. Funding will be applied to further develop, commercialize, and license a pipeline of novel, non-invasive periodontal care products designed for patients suffering from periodontal disease at all stages of severity.
